ArticlePNAS nexus2026
A proof-of-concept study on high-pressure freezing for cryopreservation.
Article in PNAS nexus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryopreservation by vitrification typically requires 30-50 v/v% of cytotoxic penetrable cryoprotective agents (CPAs) to prevent ice crystal formation during freezing and thawing, limiting its broader application. Since pressure suppresses ice crystallization, applying high pressure during vitrification may enable reducing CPA concentrations while maintaining cell viability. In this study, we used a high-pressure freezing (HPF) device, commonly used for cryofixation, to successfully cryopreserve 2D cell monolayers and 3D cell spheroids with 20-30 v/v% penetrable CPA. Compared with commonly used plunge freezing, HPF cell monolayers exhibited higher postthaw viability and better retention on the substrate, allowing for subsequent proliferation. HPF cell spheroids showed improved cell viability, metabolic activity and maintained cell-cell adhesion. Developing HPF devices specifically for cryopreservation, in combination with advanced warming techniques, holds promise for achieving vitrification with low or even no CPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.